PLoS ONE · 2012 · 38 citations · 25 references
MedicineGeneticsOncologyCancer GeneticsChemotherapyMolecular OncologyChemotherapy PharmacogenomicsGenetic Risk AssessmentPharmacogenetic TestingReceptor PolymorphismsAdvanced Glycation End ProductsAnticancer ChemotherapyCancer Risk AssociationChemotherapy Response AssessmentGenetic Predictors Of ResponseGenotype-based Drug Response PredictionNon-small Cell Lung Cancer TreatmentPlatinum-based Regimens
AIM: To explore the association between genetic polymorphisms of the receptor for advanced glycation end-products (RAGE) and susceptibility, chemotherapy response rate and prognosis of non-small cell lung cancer (NSCLC). METHOD: This is a prospective study in which 562 patients with NSCLC and 764 healthy controls were enrolled. Three RAGE genetic polymorphisms, namely, -429T/C, -374T/A and 82G/S were genotyped. Platinum-based chemotherapy was given to 432 subjects with advanced inoperable NSCLC and their responses to chemotherapy were evaluated. RESULTS: All the polymorphic genotypes of RAGE polymorphisms were associated with susceptibility for NSCLC. Only the 82G/S polymorphisms denoted a significant difference between responders and non-responders to chemotherapy. The 82SS genotype and 82S allele distribution not only increased the NSCLC risk, but also was associated with a lower chemotherapy response rate and poor prognosis, indicated by overall survival and progression free survival. CONCLUSION: The 82G/S genetic polymorphism of RAGE gene might be used as a genetic marker to screen for patients sensitive to thermotherapy and to predict the prognosis of NSCLC.
25
RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response
M. Hofmann, Steven Drury, Barry I. Hudson et al. · Genes and Immunity · 2002 · 386 citations
Life Sciences, Genetics, Immunology +14